print
Home › Medical Info › Clinical Trial Program

Clinical Trial Program

Boneca has a clinical trial program for head & neck cancers and malignant brain tumours. The trials are conducted in collaboration with the Department of Oncology, Helsinki University Central Hospital. All trials (listed below) are registered and can be found at www.clinicaltrials.gov(search: BNCT).

A clinical BNCT trial for patients diagnosed with locally recurred head and neck cancer is ongoing. This trial addresses administration of cetuximab, an anti-body directed at the epidermal growth factor receptor (EGFR), in combination with BNCT.
Click the text under to find a more information on current trial.

Boron neutron capture therapy (BNCT) combined with anti-erbB1 antibody therapy in the treatment of locally Recurred head and neck cancer; Phase I/II Study is active and recruiting patients.

List of publications

  1. Joensuu et al.: Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. Journal of Neuro-Oncology vol. 62 (2003): 123-134
  2. Kouri et al.: Undifferentiated sinonasal carcinoma may respond to single-fraction boron   neutron capture therapy; Radiotherapy and Oncology vol. 72, (2004) 83-85
  3. Kankaanranta et al.: Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int. J. Radiation Oncology, Biol. Phys., vol. 69, (2007) 475-482,
  4. Kankaanranta et al.: Boron neutron capture therapy in the treatment of locally recurred head and neck cancer: Final analysis of a phase I/II study; Int. J. Radiation Oncology, Biol. Phys. http://www.redjournal.org/article/S0360-3016(10)03463-2/abstract
  5. Kankaanranta et al, Boronphenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy, a phase I study. Int. J. Radiation Oncology, Biol. Phys.:
    http://www.redjournal.org/article/S0360-3016(10)00323-8/abstract  
  6. Kankaanranta et al,: Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as a primary therapy of large head and neck cancer with intracranial involvement; Radiotherapy and Oncology, published on-line, March 2011